Biotech Startups

Evolve Biosystems develops probiotic strains of B. infantis, including EVC001 and a next-generation drug strain INF108, aimed at supporting the infant gut microbiome and preventing necrotizing enterocolitis (NEC) in premature infants. The company works at the intersection of breast milk research and infant health in the biotech and digital/medical therapeutics space.

2 investors

Evoralis develops enzymatic recycling solutions using enzyme engineering and molecular biology to advance circular economy practices.

2 investors

Evozyne designs and builds engineered protein therapeutics using an AI-native platform, focusing on treatments for immune-mediated diseases. The company develops novel biologics and a pipeline of engineered proteins aimed at clinical use.

2 investors

Exact Sciences develops molecular diagnostic tests for cancer screening and detection, including multitarget stool DNA testing for colorectal cancer and multigene assays for breast cancer recurrence. The company serves patients and healthcare providers in the cancer diagnostics field.

2 investors

Exeliom Biosciences is a biotechnology company developing biotherapies, with work in areas such as inflammatory bowel disease (Crohn's and colitis). The company's projects have been supported by public and non-profit funding programs.

2 investors

Exero Medical develops the xBar system, which uses electrode sensors embedded in a standard surgical drain to non-invasively monitor post-operative tissue healing and detect anastomotic leaks after gastrointestinal surgery. The system provides healthcare providers with post-operative data to enable earlier detection of complications; it is currently limited to investigational use in the US.

2 investors

Exobiosphere is building a standardized space-based high-throughput testing platform that lets pharma and biotech partners run automated experiments in orbit, using microgravity combined with lab automation and bioinformatics to create more physiologically relevant 3D biology models. The company aims to accelerate drug discovery and make space a routine part of the biomedical R&D pipeline.

2 investors

Exogene is a techbio startup using a generative AI and deep learning platform to discover novel, high-affinity TCR-based (T-cell receptor) therapies for treating solid tumors. It develops cell therapies aimed at cancer treatment by mining the TCR sequence space to identify safe, non-cross-reactive receptors against shared tumor targets.

2 investors

EXOKĒRYX develops semiconductor-based technology for isolation, characterization, and analysis of extracellular vesicles to enable earlier disease and cancer detection in research settings. The company serves biomedical researchers working on disease detection and diagnostics using chip-based sensors and dielectrophoresis technology.

2 investors

Exostemtech develops exosome-based therapeutics using platform technologies derived from adult stem cells for treating diseases including osteoarthritis, obesity, diabetes, fatty liver disease, and fibrosis. The company operates in the biotechnology and therapeutic drug development sector.

2 investors

Expert Intelligence builds AI software for analytical labs in drug development, turning raw instrument data into signed, explainable, LIMS-ready results and surfacing lab-wide trends across instruments, methods, and sites. Its two products, EI Flow and EI Signal, use a proprietary Limited Sample Model to automate in-batch decisions and detect drift, serving regulated pharmaceutical QC, stability, and bioanalysis workflows.</parameter> <parameter name="founders">[]

2 investors

Epoch Biodesign is a synthetic biology company that engineers enzymes to break down plastic waste into virgin-grade feedstocks at low energy and ambient conditions. The company serves fashion, automotive, and industrial companies seeking to meet circularity targets through scalable plastic recycling solutions.

2 investors

2 investors

Faeger generates and sells agriculture-derived carbon credits, working with farmers, local governments, and agricultural cooperatives (JA) to implement decarbonization farming methods and produce traceable credits. It sells these credits to companies seeking to support regional agriculture and their own decarbonization, and also conducts R&D on crop yield improvement and climate adaptation, with a focus on Japan.

2 investors

Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.

2 investors

FASTinov develops phenotypic Antimicrobial Susceptibility Testing (AST) kits that deliver results within 2 hours directly from blood cultures, covering gram negative and gram positive panels. Its CE-marked in vitro diagnostic products serve clinical laboratories in the European Union.

2 investors

Fate Therapeutics develops investigational cellular immunotherapies to treat autoimmune diseases and cancer. The company is conducting clinical trials on product candidates under strict regulatory and ethical standards.

2 investors

Fattastic Technologies, founded in 2022, develops plant-based fat ingredients for use in food and other applications. It creates alternative fat formulations from plant-based oils for the food and ingredient industry.

2 investors

Fecundis is a biotechnology company developing sperm-centered technologies for assisted reproduction, including HyperSperm, a sequential-step kit that recreates physiological sperm capacitation in vitro for IVF and ICSI. Its products are aimed at IVF laboratories and fertility clinics to improve sperm function, embryo quality, and ART outcomes.

2 investors

FeedVax develops a platform of oral vaccines for fish aimed at aquaculture producers, reducing the need to handle animals and avoiding antibiotic use. The company targets animal production in the agtech and biotech space with a focus on sustainability.

2 investors

Feldan is a clinical-stage biotech company developing intracellular delivery technologies for therapeutic treatment of diseases. The company specializes in its Feldan Shuttle peptide-based technology to deliver antisense oligonucleotides and other therapeutics to cellular targets, with current programs targeting basal cell carcinoma and respiratory diseases.

2 investors

Fieldstone Bio builds engineered biosensors combined with hyperspectral imaging to detect and map critical minerals such as gold, copper, and arsenic in soil samples, cores, and tailings. The platform serves mining and mineral exploration teams, providing high-resolution measurement data to guide sampling, drilling, and processing decisions.

2 investors

Firefly Bio develops antibody-drug conjugates (ADCs) that use novel classes of payloads, drawing on a research team experienced in ADC discovery and development. The company operates in the oncology and immunology biotech space.

2 investors

Firma is a contract research organization that supports clinical trials with decentralized trial capabilities, biometric monitoring, and in-home patient visits. The company serves pharmaceutical and biotech companies conducting drug development across therapeutic areas.

2 investors